AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Katsuyoshi Matsuoka,Mamoru Watanabe,Toshihide Ohmori,Koichi Nakajima,Tetsuya Ishida,Yoh Ishiguro,Kazunari Kanke,Kiyonori Kobayashi,Fumihito Hirai,Kenji Watanabe,Hidehiro Mizusawa,Shuji Kishida,Yoshiharu Miura,Akira Ohta,Toshifumi Kajioka,Toshifumi Hibi,AJM300 Study Group,Satoshi Motoya,Atsuo Maemoto,Mikihiro Fujiya,Toshifumi Ashida,Mitsuru Goto,Takayuki Matsumoto,Yasuo Suzuki,Yukihiro Hamahata,Tomoo Nakagawa,Naoya Kato,Jun Kato,Yutaka Endo,Ryoichi Suzuki,Koichiro Matsuda,Naoki Ohmiya,Shinji Katsushima,Shuhei Hosomi,Ken-Ichi Tarumi,Chiyuki Watanabe,Mitsuru Saito,Yuichiro Yokoyama,Tomoki Inaba,Yasuhisa Sakata,Hitoshi Hongo,Tomoyoshi Shibuya,Kazuhiko Kawakami,Yoichi Kakuta,Atsushi Irisawa,Naoki Yoshimura,Katsuyuki Fukuda,Takayuki Shirai,Hitoshi Ichikawa,Junko Nagata,Takayoshi Suzuki,Kaoru Yokoyama,Takashi Tomidokoro,Yuichiro Kojima,Masahiro Yamada,Hideko Yamamoto,Takayuki Yamamoto,Noriyuki Horiki,Hirozumi Obata,Satoko Inoue,Shinji Tanaka,Tatsuya Toyokawa,Masaki Kunihiro,Takashi Hisabe,Shinichi Ogata,Fuminao Takeshima,Kayoko Matsushima,Nobuyuki Matsuhashi,Hirotake Sakuraba,Masahiro Iwabuchi,Akihiko Tsuchiya,Kan Uchiyama,Takanori Kanai,Masanao Nakamura,Tadashi Yokoyama,Nobuyuki Hida,Keiichi Mitsuyama,Taro Osada,Sakiko Hiraoka,Tomoyuki Tsuzuki,Takashige Masuo,Ryota Hokari,Taku Kobayashi,Masayuki Saruta,Masao Araki,Hiroshi Araki,Masahito Shimizu,Masakazu Kikuchi,Takahiro Nishikawa,Hidetoshi Takedatsu,Kunihiko Aoyagi,Toshiaki Ochiai,Nobuo Toda,Yuji Mizokami,Masakazu Nagahori,Kazuhiro Matsueda,Hitoshi Kino,Akira Kanamori,Tsunehiro Suzuki,Toshiharu Sakurai,Masatoshi Kudo,Atsuo Kitano,Tadakazu Hisamatsu,Shinji Kumagai,Tomoyuki Ninomiya,Kenichiro Mori,Shun-Ichi Yoshida,Mitsuhide Goto
DOI: https://doi.org/10.1016/S2468-1253(22)00022-X
Abstract:Background: AJM300 is an oral, small-molecule α4-integrin antagonist. We assessed the efficacy and safety of AJM300 in patients with moderately active ulcerative colitis. Methods: This multicentre, randomised, double-blind, placebo-controlled, phase 3 study consisted of two phases: a treatment phase and an open-label re-treatment phase. The study was done at 82 hospitals and clinics in Japan. Patients with a Mayo Clinic score of 6-10, endoscopic subscore of 2 or more, rectal bleeding subscore of 1 or more, and an inadequate response or intolerance to mesalazine were enrolled. Patients were randomly allocated (1:1) via a website to either AJM300 (960 mg) or placebo by the minimisation method, which was adjusted centrally by dynamic assignment against the Mayo Clinic score (≥6 to ≤7, ≥8 to ≤10 points), any use of corticosteroid, anti-TNFα antibody, or immunosuppressants during the disease-active period (yes vs no), duration of induction therapy until randomisation (<4 weeks vs ≥4 weeks) as the minimisation factors. Patients, investigators, site staff, assessors, and the sponsor were masked to treatment assignments. The study drug was administered orally, three times daily, for 8 weeks, and continued for up to 24 weeks if endoscopic remission was not achieved or rectal bleeding did not stop. The primary endpoint was the proportion of patients with a clinical response at week 8, and was analysed in the full analysis set. Clinical response was defined as a reduction in Mayo Clinic score of 30% or more and 3 or more, a reduction in rectal bleeding score of 1 or more or rectal bleeding subscore of 1 or less, and an endoscopic subscore of 1 or less at week 8. The study is registered with ClinicalTrials.gov, NCT03531892, and is closed to recruitment. Findings: Between June 6, 2018, and July 22, 2020, 203 patients were randomly assigned to AJM300 (n=102) or placebo (n=101). At week 8, 46 (45%) patients in the AJM300 group and 21 (21%) patients in the placebo group had a clinical response (odds ratio 3·30, 95% CI 1·73-6·29; p=0·00028). During the 8-week treatment and 16-week extension treatment periods, adverse events occurred in 39 (39%) of 101 patients in the placebo group and 39 (38%) of 102 patients in the AJM300 group. We found no difference in the incidence of adverse events between groups or after repeated administration of AJM300. The most common adverse event was nasopharyngitis (11 [11%] of 101 patients in the placebo group and ten [10%] of 102 patients in the AJM300 group). The most common treatment-related adverse event was also nasopharyngitis (four [4%] of 101 patients in the placebo group and three [3%] of 102 patients in the AJM300 group). Most adverse events were mild-to-moderate in severity. No deaths were reported. A serious adverse event was reported in the AJM300 group (one patient with anal abscess), but this was judged to be unrelated to study drug. Interpretation: AJM300 was well tolerated and induced a clinical response in patients with moderately active ulcerative colitis who had an inadequate response or intolerance to mesalazine. AJM300 could be a novel induction therapy for the treatment of patients with moderately active ulcerative colitis. Funding: EA Pharma and Kissei Pharmaceutical. Translation: For the Japanese translation of the abstract see Supplementary Materials section.